Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Type B adverse drug reactions reported by an immunoallergology department
Publication

Publications

Type B adverse drug reactions reported by an immunoallergology department

Title
Type B adverse drug reactions reported by an immunoallergology department
Type
Article in International Scientific Journal
Year
2018
Authors
Costa, MJ
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Herdeiro, MT
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Polonia, J
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Title: Pharmacy PracticeImported from Authenticus Search for Journal Publications
Vol. 16
Final page: 1070
ISSN: 1885-642X
Indexing
Other information
Authenticus ID: P-00P-P23
Resumo (PT):
Abstract (EN): Objective: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC). Methods: An observational, descriptive and retrospective study was conducted, based in a spontaneous report system. Participants were all the patients from the IAD, with suspected ADR, reported to NPC by specialists after the study was completed. Results: Studied population had a median age of 41 years, with the predominance of the female gender (73.2%). Allergic rhinitis and asthma were the most frequent comorbidities. All studied ADR were type B, 89.6% were serious, 86.4% unexpected and 2.6% associated with drugs that presented less than 2 years in the market. The most represented drug classes were the non-steroidal anti-inflammatory drugs (NSAIDs) (52.6%) and antibiotics (25.2%). Skin symptoms represented 61.2% of the reported complaints. About 52.9% of these ADR occurred in less than one hour after intake. The most frequent ADR treatment at the time of the reaction was drug interruption (86.2%), followed by the prescription of anti-histamines (42.2%). Conclusions: Reported ADR to NPC by the Drug Alert Unit were mainly serious, unexpected, associated with NSAIDs and antibiotics and related with marketing authorization medicines older than two years. These results could be very useful to develop strategies to prevent the clinical and economic consequences of ADR.
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

What is 'pharmaceutical care' in 2013? (2013)
Another Publication in an International Scientific Journal
Van Mil, JWF; Fernandez Llimos, F
Scholarly publishing depends on peer reviewers (2018)
Another Publication in an International Scientific Journal
Fernandez-Llimos F.; Berti A.D.; Yeung D.; Yusuff K.B.; El Zowalaty M.E.; Adane E.D.; Al-Aqeel S.; Al-Jumaili A.A.; Alili-Idrizi E.; Andelkovic M.; Aranha A.; Arief M.; Arkaravichien W.; Armoiry X.; Attarabeen O.F.; Ayoub N.; Bajorek B.V.; Beninger P.; Billups S.J.; Bowen J.F....(mais 80 authors)
Quality of drug information for healthcare professionals: The ARCA acronym (2015)
Another Publication in an International Scientific Journal
Fernandez Llimos, F
Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions (2021)
Another Publication in an International Scientific Journal
Tonin, FS; Aznar Lou, I; Pontinha, VM; Pontarolo, R; Fernandez Llimos, F
Pharmacy Practice suffered a plagiarism case (2012)
Another Publication in an International Scientific Journal
Fernandez Llimos, F

See all (27)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-22 at 14:03:52 | Privacy Policy | Personal Data Protection Policy | Whistleblowing